Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.48 |
| ▸ | ESR1 | P03372 | 9/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26690821 | 0.79 | TRPV4 (0.45) | TRPV4ESR1ESR2KHKCES2 | |
| SCHEMBL18894081 | 0.76 | ESR1 (0.40) | TRPV4ESR1ESR2KHKCES2 | |
| SCHEMBL19780236 | 0.76 | ESR1 (0.40) | TRPV4ESR1ESR2KHKCES2 | |
| SCHEMBL18396988 | 0.72 | ESR1 (0.40) | TRPV4ESR1ESR2KHKCES2 | |
| SCHEMBL18397212 | 0.72 | ESR1 (0.40) | TRPV4ESR1ESR2KHKCES2 | |
| SCHEMBL19768986 | 0.72 | TRPV4 (0.36) | TRPV4ESR1ESR2KHKAR | |
| SCHEMBL21883544 | 0.72 | TRPV4 (0.36) | TRPV4ESR1ESR2KHKAR | |
| SCHEMBL21883710 | 0.72 | TRPV4 (0.36) | TRPV4ESR1ESR2KHKAR | |
| SCHEMBL21883627 | 0.69 | TRPV4 (0.45) | TRPV4ESR1ESR2AR | |
| SCHEMBL809090 | 0.69 | TRPV4 (0.48) | TRPV4ESR1ESR2KHKCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | TRPV4 1233/4885ESR1 1952/4885ESR2 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.